According to data and analytics firm GlobalData, the burden of hospitalized incident cases of methicillin-resistant Staphylococcus aureus (MRSA) is set to grow from 714,000 to 791,000 cases by 2023.
Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome,...
SolasCure is moving forward with its maggot-derived wound gel, after publishing the results of its recent phase 2 clinical trial in a leading wound care journal.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple...
AN2 Therapeutics recently announced a decision to voluntarily pause enrollment of the phase 3 portion of the phase 2/3 trial, EBO-301, in light of potentially lower than expected efficacy data obtained from the phase 2 trial.
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
Inspired Thinking Group (ITG) the technology-led multichannel marketing activation business, has launched ITG Health to deliver an ‘automation-first approach’ to the life sciences industry.
Vial, a CRO providing clinical trial management services, has partnered with biopharma company Nielsen BioSciences to study the safety and efficacy of CANDIN, a treatment for common warts.
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.
The clinical stage company announces that its potential treatment for relapsed or refractory multiple myeloma receives nod for speedier review by the FDA.
Israel’s Sheba Medical Center, the largest hospital in the Middle East region, has initiated a collaborative project with Regeneron focused on oncology research and accelerating the development of potential novel therapeutics.
The DATAcc has released a collection of open-access resources that are intended to help users build inclusivity into digital health measurement products.
Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
